HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib von Wang, Y., Jiang, T., Qin, Z., Jiang, J., Wang, Q., Yang, S., Rivard, C., Gao, G., Ng, T.L., Tu, M.M., Yu, H., Ji, H., Zhou, C., Ren, S., Zhang, J., Bunn, P., Doebele, R.C., Camidge, D.R., Hirsch, F.R.

Volltext

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study von Hong, D.S., Bauer, T.M., Lee, J.J., Dowlati, A., Brose, M.S., Farago, A.F., Taylor, M., Shaw, A.T., Montez, S., Meric-Bernstam, F., Smith, S., Tuch, B.B., Ebata, K., Cruickshank, S., Cox, M.C., Burris, H.A., Doebele, R.C.

Volltext

Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy von McCoach, C.E., Blumenthal, G.M., Zhang, L., Myers, A., Tang, S., Sridhara, R., Keegan, P., Pazdur, R., Doebele, R.C., Kazandjian, D.

Volltext

A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced... von Doebele, R.C., Conkling, P., Traynor, A.M., Otterson, G.A., Zhao, Y., Wind, S., Stopfer, P., Kaiser, R., Camidge, D.R.

Volltext

301 INVITED ALK in NSCLC – Paving the Way for Oncogene-directed Therapy von Doebele, R

Volltext

Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC von Bokhari, A.A., Lai, W-Y., Le, A.T., Gabre, J.L., Chuang, T-P., Fransson, S., Bergman, B., Djos, A., Chen, N., Martinsson, T., Van den Eynden, J., Doebele, R.C., Palmer, R.H., Hallberg, B., Umapathy, G.

Volltext

Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001 von Demetri, G.D., Paz-Ares, L., Farago, A.F., Liu, S.V., Chawla, S.P., Tosi, D., Kim, E.S., Blakely, C., Krauss, J.C., Sigal, D., Bazhenova, L., John, T., Besse, B., Wolf, J., Seto, T., Chow-Maneval, E., Multani, P.S., Johnson, A.D., Simmons, B., Doebele, R.C.

Volltext

PL01.01 Tumor-Agnostic Biologically Driven Treatments: An Endless Dream? von Doebele, R.

Volltext

Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy von McCoach, C E, Blumenthal, G M, Zhang, L, Myers, A, Tang, S, Sridhara, R, Keegan, P, Pazdur, R, Doebele, R C, Kazandjian, D

Volltext

Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001 von Paz-Ares, L., Doebele, R.C., Farago, A.F., Liu, S.V., Chawla, S.P., Tosi, D., Blakely, C.M., Krauss, J.C., Sigal, D., Bazhenova, L., John, T., Besse, B., Wolf, J., Seto, T., Chow-Maneval, E., Ye, C., Simmons, B., Demetri, G.D.

Volltext

Randomized phase II trial of osimertinib with or without local consolidation therapy (LCT) for patients with EGFR-mutant metastatic NSCLC (NORTHSTAR) von Elamin, Y.Y., Antonoff, M., Blakely, C., Baggstorm, M., Bivona, T., Le, X., Louie, A.V., Doebele, R.C., Rusthoven, C., Lee, P., Govindan, R., Swisher, S.G., Papadimitrakopoulou, V.A., Heymach, J.V., Gomez, D.R.

Volltext

Entrectinib in NTRK-fusion positive gastrointestinal cancers: integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1, and ALKA-372-001) von Siena, S., Demetri, G., Doebele, R., Chae, Y., Conkling, P., Garrido-Laguna, I., Garrido, P., Rolfo, C., Sigal, D., Eng, S., Simmons, B., Ye, C., Ciardiello, F.

Volltext

Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2 von Barlesi, F., Drilon, A., De Braud, F., Cho, B.C., Ahn, M.J., Siena, S., Krebs, M.G., Lin, C.C., John, T., Tan, D.S.W., Seto, T., Dziadziuszko, R., Arkenau, H.-T., Rolfo, C., Wolf, J., Ye, C., Riehl, T., Eng, S., Doebele, R.C.

Volltext

MS 25.05 Novel Fusions von Doebele, R.

Volltext

Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001 von Demetri, G.D., Paz-Ares, L., Farago, A.F., Liu, S.V., Chawla, S.P., Tosi, D., Kim, E.S., Blakely, C.M., Krauss, J.C., Sigal, D., Bazhenova, L., John, T., Besse, B., Wolf, J., Seto, T., Chow-Maneval, E., Multani, P.S., Johnson, A., Simmons, B., Doebele, R.C.

Volltext

Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC von Peters, T. L., Patil, T., Le, A. T., Davies, K. D., Brzeskiewicz, P. M., Nijmeh, H., Bao, L., Camidge, D. R., Aisner, D. L., Doebele, R. C.

Volltext

Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours von Paz-Ares, L., Barlesi, F., Siena, S., Ahn, M.-J., Drilon, A., Conley, A., Rolfo, C., Wolf, J., Seto, T., Doebele, R., Kapre, A., Chen, D., McCallum, S., Osborne, S., Demetri, G.

Volltext

P1.14-58 A Phase II Study to Evaluate Neoadjuvant Osimertinib for Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer von Rotow, J., Urisman, A., Mccoach, C., Jahan, T., Bivona, T., Jones, K., Gupta, A., Do, H., Riess, J., Aisner, D., Doebele, R., Jablons, D., Kratz, J., Blakely, C.

Volltext

Clinical Activity of Crizotinib in Ros1-Rearranged Non-Small Cell Lung Cancer von Shaw, A., Ou, S.I., Bang, Y., Camidge, R., Solomon, B., Salgia, R., Riely, G.J., Varella-Garcia, M., Shapiro, G., Costa, D., Doebele, R., Le, L.P., Zheng, Z., Stephenson, P., Shreeve, S.M., Tye, L., Christensen, J., Wilner, K., Clark, J., Iafrate, A.

Volltext

Entrectinib in patients with advanced or metastatic NTRK fusion- positive solid tumours: integrated analysis of three phase 1-2 trials (vol 21, pg 271, 2020) von Doebele, R. C., Drilon, A., Paz-Ares, L.

Volltext